ArticleFrontiers in immunology2026
Adolescent autoimmune encephalitis with dual positive anti-Drebrin and anti-mGluR2 antibodies: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, no research has reported the coexistence of anti-Drebrin antibody and anti-mGluR2 antibody in patients with autoimmune encephalitis (AE). This study presents the first detailed case of AE with dual positivity for these antibodies, aiming to enrich the database of double antibody-positive AE and provide clinical insights for diagnosis and treatment. We report a 15-year-old male patient whose main clinical manifestations were mental abnormalities and epileptic seizures, accompanied by frequent irritability and rambling speech. Serological and cerebrospinal fluid (CSF) analyses showed positive results for Drebrin and mGluR2 antibodies. The titer of anti-Drebrin antibody was 1:1000 (serum) and 1:1 (CSF), while the titer of anti-mGluR2 antibody was 1:32+ (serum) and 1:1+ (CSF). Based on the clinical manifestations and diagnostic results, the patient was diagnosed with AE, with concurrent positive anti-Drebrin and anti-mGluR2 antibodies in both serum and CSF. Significant improvement was achieved following immunotherapies, including steroid pulse therapy and intravenous immunoglobulin infusion. Readmission one month later for relapse responded well to renewed immunotherapy, and the patient was discharged with marked improvement. No recurrence was observed during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.